Aromatase inhibitors and monoclonal anti-HER2 antibodies having a synergistic or super-additive effect as an antitumour agent

摘要

The use of an aromatase inhibitor e.g. exemestane, fadrozole, letrozole and anastrozole and an antibody against HER2 (p185) e.g. trastuzumab, in amounts effective to produce a superadditive or synergistic therapeutic effect in the manufacture of a medicament to treat a human being suffering from an hormone-dependent disorder characterized by the overexpression of HER2 is described.